#+setupfile: ./hugo_setup.org
#+hugo_slug: Henry's_Clinical_diagnosis_and_management_by_McPherson_and_Pincus_in_2016
#+TITLE: Henry's Clinical diagnosis and management by McPherson and Pincus in 2016
* Part 4: Hematology and transfusion medicine
** hematopathology (510-734 = 224)
*** 30. Basic examination of blood and bone marrow (510-539)
**** Hematology principles and procedures
***** Hemoglobin
***** Hematocrit (packed cell volume)
***** Erythrocyte indices
***** Manual blood cell counts
***** Instrument technology
**** Blood film examination
***** Examination of wet preparations
***** Making and staining blood films
***** Erythrocytes
***** Leukocytes on peripheral blood smear examination
***** Platelets on peripheral blood smear examination
***** Erythrocytes
*** 31. Hematopoiesis (540-558)
*** 32. Erythrocytic disorders (559-605)
**** 32.1 Anemias
***** General manifestations
***** Impaired production--Iron deficiency anemia
****** Iron metabolism
****** Iron deficiency anemia
******* Clinical features
******* Laboratory features
******** blood
******** marrow
******** serum iron
******** serum iron-binding capacity
******** percent saturation of TIBC
******** serum ferritin
******** erythrocyte porphyrins
******** serum transferrin receptors
******** serum transferrin receptors
******** serum transferrin receptor-to-serum ferritin ratio
******** reticulocyte hemoglobin content
******** hepcidin level
******* Differential diagnosis
******* Management
****** Iron-refractory iron deficiency anemia (IRIDA)
***** Impaired production--Megaloblastic anemia
****** Macrocytosis with normoblastic marrow
****** Megaloblastic anemia
******* blood
******* marrow
******* erythrokinetics
****** Cobalamin (Vitamin B12) metabolism
****** Cobalamin deficiency
******* Inadequate intake
******* Defective production of intrinsic factor
****** Pernicious anemia
******* clinical features
******* gastric findings
******* immune abnormalities
******* pernicious anemia in children
******* gastrectomy
******* defective absorption of cobalamin
******** malabsorption syndromes
******** lack of availability
******* diagnosis of cobalamin deficiency
******** therapeutic trial
******** serum cobalamin assay
******** methylmalonic acid and homocysteine assays
******** deoxyuridine suppression test
******* detecting the cause of cobalamin deficiency
****** Folic acid metabolism
******* The folate-cobalamin relationship
****** Folic acid deficiency
******* Inadequate intake of folate
******** Evolution of laboratory abnormalities
******** Nutritional folate defiency
******** Liver disease
******* Defective absorption of folate
******* Increased requirement for folate
******* Inadequate utilization of folate
******* Diagnosis of folate deficiency
******** Serum and red cell folate
******** Urinary formiminoglutamic acid (FIGLU)
******** Deoxyuridine suppression test
******** Plasma homocysteine assay
******* Acute megaloblastic anemia
****** Therapy for megaloblastic anemia
****** Other defects of nucleoprotein synthesis
******* congenital defects
******* synthetic inhibitors
******* refractory anemias
***** Impaired production--Other
****** Anemia of chronic disease
****** Anemia of renal insufficiency
****** Anemia of liver disease
****** Anemia in endocrine disease
****** Anemia associated with bone marrow infiltration (myelophthisic anemia)
****** Aplastic anemia
****** Pure red cell aplasia
******* Transitory arrest of erythropoiesis
******* Transient erythroblastopenia of childhood
******* Congenital red cell aplasia (Diamond-Blackfan anemia; Congenital hypoplastic anemia)
******* Acquired pure red cell aplasia
****** Sideroblastic anemia
****** Refractory anemia
****** Congenital dyserythropoietic anemias
***** Blood loss anemia
****** Acute posthemorrhagic anemia
****** Chronic posthemorrhagic anemia
***** Hemolysis--general
****** Erythrocyte survival studies
****** Hemoglobin destruction
******* Blood film
******* Bone marrow
***** Hemolysis--membrane disorders
****** Hereditary spherocytosis
****** Hereditary elliptocytosis
***** Hemolysis--hemoglobin disorders
****** Normal hemoglobins
******* Hb A (a2b2)
******* Hb F (a2g2)
******* Hb A2 (a2d2)
******* Embryonic hemoglobins
******* The globin gene clusters
******* Glycosylated hemoglobins
****** Laboratory investigation of hemoglobinopathies and thalassemias
****** Abnormal hemoglobin synthesis
****** Sickling disorders
****** Common alpha chain variants
****** Disorders of hemoglobin function
***** Thalassemias
****** Molecular defects
****** Beta-thalassemias
******* homozygous beta thalassemia (thalassemia major; Cooley's anemia)
******* heterozygous beta-thalassemia (beta thalassemia trait; thalassemia minor; Cooley's trait)
******* beta thalassemia trait with normal hemoglobin a2
******* delta-beta 0 thalassemia 
******* delta-beta +: Lepore hemoglobins
****** Hereditary persistence of fetal hemoglobin
****** Alpha thalassemias
******* alpha thalassemia syndromes
******** hemoglobin Bart's hydrops fetalis
******** hemoglobin H disease
******** alpha thalassemia trait: heterozygous alpha 0 thalassemia (* * / alpha alpha) or homozygous alpha + thalassemia (* alpha/ * alpha)
******** silent carrier alpha thalassemia (heterozygous alpha+ thalassemia) (alpha alpha/-alpha) 
******** hemoglobin constant spring (alphaCS alpha/)
****** Screening and prenatal diagnosis of hemoglobin disorders
***** Hemolysis--metabolic disorders
****** Erythrocyte metabolism
****** Glucose-6-phosphate dehydrogenase deficiency
****** Pyruvate kinase (PK) deficiency
****** Other glycolytic enzyme deficiencies
****** Pyrimidine-5'-nucleotidase deficiency
***** Hemolysis--acquired; extrinsic
****** Chemical agents
****** Physical agents
****** Infectious agents
****** Immune hemolytic anemias
***** Laboratory investigations of anemia
****** Macrocytic anemia (increased MCV)
****** Microcytic and hypochromic anemias (decreased MCV and MCH)
******* iron deficiency anemias
******** low iron low TIBC
******* anemia of chronic disease
******** low iron normal TIBC
******* thalassemia
******** normal to elevated iron with hypochromic anemia and basophilic stippling
******* sideroblastic anemia
****** Normocytic and normochromic anemias (normal MCV)
******* optimal marrow response: reticulocyte production index greater than two
******** direct antiglobulin (Coombs) test
******* inadequate marrow response: reticulocyte production index less than two
**** 32.2 Polycythemia
***** Relative polycythemia
***** Absolute polycythemia
***** Measurement of erythrocyte and plasma volume
**** 32.3 Porphyrias
***** Physiology
***** Approach to the porphyrias
***** Clinical porphyrias and their biochemical basis
***** Analytic techniques
*** 33. Leukocytic disorders (606-658)
**** 33.1 Leukocytes
**** 33.2 Nonneoplastic disorders
***** Granulocytic and monocytic disorders
***** Lymphocytic and plasmacytic disorders
***** Leukemoid reactions
**** 33.3 Neoplastic disorders primarily involving leukocytes
***** Overview of hematopoietic neoplasms
****** CML t(9;22)(q34;q11) BCR/ABL translocation targeted by imatinib / Gleevec
****** promyelocytic leukemia t(15;17)(q22;q12) PML/RARA abnormal retinoic acid receptor responds to all-trans retinoic acid
***** Chronic myeloproliferative disorders
****** Introduction
******* Includes clonal proliferations of pluripotent stem cells that can differentiate along granulocytic, erythroid, and megakaryocytic lines
******* The chronic course may terminate as acute leukemia, myelofibrosis, or coagulopathy 
****** Chronic myelogenous leukemia
******* +/* BCR/ABL1
******* Clinical features
******** Young and middle aged; >50
******** Anemia, weight loss, splenomegaly, fever and night sweats
******* Laboratory features
******** Blood
********* increased leukocyte count (usually >5e9/L , possibly >30e9/L )
********* normocytic anemia
******** Marrow
********* markedly hypercellular due to granulocytic proliferation
********* failure to aspirate due to cellular density and increased reticulin
********* blue pigment laden macrophages
******** Neutrophil alkaline phosphatase
********* greatly reduced or absent in more than 90% of patients
********* this is in contrast to elevations seen in PV, IMF, and leukemoid reactions
******** Cytogenetic abnormalities
********* t(9;22)(q34;q11) in more than 95%
********** the BCR-ABL1 fusion results in a novel RNA transcript and associated growth factor with tyrosine kinase activity higher than that of the normal p145 protein encoded by the ABL1 gene
********* Major and minor breakpoint regions of BCR
********** M-BCR --> p210
********** mu region --> p230
********** m-BCR --> p190 --> usually associated with ALL
******** Other findings
********* Serum cobalamin and transcobalamin are usually increased as a result of increased transcobalamin I reflecting the size of the total blood granulocyte pool
********* Lysozyme (muramidase) is also increased
******* Course
******** Untreated patients or those who fail treatment progress to a more aggressive or accelerated phase characterized by features of progressive myeloproliferation
******** Blast phase is a progression to acute leukemia defined by >20% blasts in the blood or BM which is myeloid lineage in >70% of cases. In approximately 1/3 of cases ALL mostly of precursor B-lineage appears.
****** Chronic neutrophilic leukemia
****** Polycythemia vera
******* JAK2 V617F
****** Primary myelofibrosis
****** Essential thrombocythemia
****** MPN with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1
****** Chronic eosinophilic leukemia
****** Mastocytosis
****** Myelodysplastic and myelodysplastic/myeloproliferative neoplasms
****** Myelodysplastic/myeloproliferative disease, unclassifiable
****** Myelodysplastic syndromes
***** Acute myeloid leukemia
****** Acute leukemia with recurrent genetic abnormalities
******* AML with balanced translocations/inversions
******** AML with t(8;21)(q22;q22) RUNX1-RUNX1T1
******** AML with inv(16)(p13q22) or t(16;16)(p13.1;q22), CBF beta/MYH11
******** Acute promyelocytic leukemia with t(15;17)(q22;q12) PML/RARA, and variants
******** AML with t(9;11)(p22;q23); MLLT3-MLL
******** AML with t(6;9)(p23;q34); DEK-NUP214
******** AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1
******** AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1
******* AML with gene mutations
******** AML with FLT3 mutation
******** AML with NPM1 mutation
******** AML with CEBPA mutation
****** Acute myeloid leukemia with myelodysplasia-related changes
****** Acute myeloid leukemia, NOS
****** Myeloid proliferations related to Down syndrome
****** Acute leukemias of ambiguous lineage
***** Precursor lymphoid neoplasms
****** B lymphoblastic leukemia/lymphoma
****** B lymphoblastic leukemia/lymphoma, NOS
***** Mature B cell neoplasms
****** Monoclonal B cell lymphocytosis
****** Chronic lymphocytic leukemia/Small lymphocytic lymphoma
******* M>F over 60 years
******* Fatigue, lymphadenopathy WBC > 5e3/uL, anemia, thrombocytopenia
****** B cell prolymphocytic leukemia
****** Splenic marginal zone lymphoma
****** Hairy cell leukemia
****** Splenic B cell lymphoma/leukemia, unclassifiable
****** Hairy cell leukemia variant
****** Lymphoplasmacytic lymphoma
****** Heavy chain diseases
****** Plasma cell neoplasms
******* MGUS
******* plasma cell myeloma
****** Monoclonal immunoglobulin deposition diseases
****** Extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue
****** Nodal marginal zone lymphoma
****** Follicular lymphoma
****** Mantle cell lymphoma
****** Diffuse large B cell lymphoma, NOS
****** Lymphomatoid granulomatosis
****** Primary mediastinal thymic large B cell lymphoma
****** Intravascular large B cell lymphoma
****** ALK-positive large B cell lymphoma
****** Plasmablastic lymphoma
****** Large B cell lymphoma arising in HHV8-associated multicentric Castleman's disease
****** Primary effusion lymphoma
****** Burkitt lymphoma
****** B cell lymphoma unclassifiable with features intermediate between DLBCL and Burkitt lymphoma
****** B cell lymphoma unclassifiable with features intermediate between DLBCL and classical Hodgkin lymphoma
***** Mature T cell and natural killer cell neoplasms
****** T-prolymphocytic leukemia
****** Large granular lymphocyte leukemia
****** Chronic-lymphoproliferative disorders of NK cells
****** Aggressive NK cell leukemia
****** EBV-positive T cell lymphoproliferative disorders of childhood
****** Adult T cell leukemia-lymphoma
****** Extranodal NK/T cell lymphoma, Nasal type
****** Enteropathy-associated T cell lymphoma
****** Hepatosplenic T cell lymphoma
****** Subcutaneous panniculitis-like T cell lymphoma
****** Mycosis fungoides and Sezary syndrome
****** Primary cutaneous CD30-positive T cell lymphoproliferative disorder
****** Primary cutaneous gamma delta T cell lymphoma
****** Angioimmunoblastic T cell lymphoma
****** Peripheral T/NK cell lymphoma, unspecified
****** Anaplastic large cell lymphoma
****** Anaplastic large cell lymphoma ALK negative
***** Hodgkin lymphoma
****** Classical hodgkin lymphoma
******* nodular sclerosis
******* mixed cellularity
******* lymphocyte depletion
****** Nodular lymphocyte-predominant HL
****** Nodular lymphocyte-rich classical HL
***** Immunodeficiency-associated lymphoproliferative disorders
****** HIV-associated lymphomas
****** Posttransplant lymphoproliferative disorders
***** Histiocytic and dendritic cell neoplasms
****** Hemophagocytic syndromes, or hemophagocytic lymphohistiocytosis (HLH)
****** Langerhans cell histiocytosis
****** Interdigitating dendritic cell sarcoma/tumor
****** Follicular dendritic cell sarcoma/tumor
****** Dendritic cell sarcoma, not otherwise specified
*** 34. The flow cytometric evaluation of hematopoietic neoplasia (659-679)
**** 
*** 35. Immunohematology (680-734)
** transfusion medicine
*** 36. Transfusion medicine
*** 37. Hemapheresis
*** 38. Tissue banking and progenitor cells
* Part 5: Hemostasis and Thrombosis
** coagulation
*** 39. Coagulation and fibrinolysis
*** 40. Platelet disorders and von Willebrand disease
*** 41. Laboratory approach to thrombotic risk
*** 42. Antithrombotic therapy
* Part 6: Immunology and immunopathoogy
** 43. Overview of the immune system and immunologic disorders
** 44. Immunoassays and immunochemistry
** 45. Laboratory evaluation of the cellular immune system
** 46. Laboratory evaluation of immunoglobulin function and humoral immunity
** 47. Mediators of inflammation: complement, cytokines, and adhesion molecules
** 48. Mediators of inflammation: cytokines and adhesion molecules
** 49. Human leukocyte antigen: the major histocompatibility complex of man
** 50. The major histocompatibility complex and disease
** 51. Immunodeficiency disorders
** 52. Clinical and laboratory evaluation of systemic rheumatic diseases
** 53. Vasculitis
** 54. Organ-specific autoimmune diseases
** 55. Allergic diseases
* Part 8: Molecular pathology
** 65. Introduction to molecular pathology
** 66. Molecular diagnostics: basic principles and techniques
** 67. Polymerase chain reaction and other nucleic acid amplification technologies
** 68. Hybridization array technologies
** 69. Applications of cytogenetics in modern pathology [[file:progress_indicators.org][progress indicators]]
*** Definitions
*** Cytogenetics
**** Chromosomes
***** Chromosome structure
***** Cell culture
****** specimens
****** cell culture technique
***** Staining
***** Karyotype analysis
****** computer-assisted imaging
***** Fluorescence in situ hybridization
****** technique
****** multicolor FISH
***** Microarray technology
**** Chromosome abnormalities
***** numerical abnormalities
****** euploidy
****** aneuploidy
***** structural chromosome abnormalities
***** nomenclature
*** Clinical applications
**** Constitutional cytogenetics
***** prenatal
***** postnatal
***** childhood and adult
**** Cancer genetics
**** Cytogenetic disorders
***** Chromosomal Aneuploidy Syndromes
****** Autosomal Aneuploidies
****** Sex Chromosome Aneuploidies
***** Other Sex Chromosome Abnormalities
***** Structural Chromosome Anomalies
***** Microdeletion Syndromes and Contiguous Gene Syndromes
**** Other cytogenetic phenomena
***** Fragile X Syndrome
***** Breakage Syndromes
****** See list in table 69-6
*** Summary
** 70. Establishing a molecular diagnostics laboratory
** 71. Molecular diagnosis of genetic diseases
** 72. Identity analysis: use of DNA analysis in parentage, forensic, and missing persons testing
** 73. Pharmacogenomics and personalized medicine
* Part 9: Molecular pathology
** 74. Diagnosis and management of cancer using serologic and other body fluid markers
** 75. Oncoproteins and early tumor detection
** 76. Molecular diagnosis of hematopoietic neoplasms [[file:progress_indicators.org][progress indicators]]
*** Role of clinical molecular diagnostics in hematologic cancers
*** Molecular diagnosis of leukemias
**** Gene fusion concept in leukemia and the basis for reverse-transcription polymerase chain reaction analysis
**** Acute myeloid leukemias
***** Acute Promyelocytic Leukemia: t(15;17) (q22;q21)/PML-RARA Abnormality
***** Core Binding Factor–Related Acute Myeloid Leukemias: t(8;21)(q22;q22)/RUNX1-RUNX1T1 and Inv(16)(p13q22) or t(16;16)(p13;q22)/CBFB-MYH11 Abnormalities
***** Acute Myeloid Leukemia with Other Translocations
****** AML with 11q23/MLL
****** AML with t(6;9)(p23;q34)/DEK-NUP214
****** AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)/RPN1-EVI1
****** AML (Megakaryoblastic) with t(1;22)(p13;q13)/RBM15-MKL1
****** Acute Myeloid Leukemias with FLT3, NPM1, and CEBPA Gene Mutations
***** FLT3 Mutations in Acute Myeloid Leukemia
***** NPM1 Mutations in Acute Myeloid Leukemia
***** CEBPA Mutations in Acute Myeloid Leukemia
***** Other Gene Mutations in Acute Myeloid Leukemias
****** Mutations involving many other genes, including WT1 (see below), MLL, TET2, JAK2, IDH1/IDH2, EZH2, PLK1, NRAS, and KRAS, have been associated with prognostic or biologic importance in AML.
**** Acute lymphoblastic leukemia/lymphoma--B and T cell lineage
***** B Cell Lymphoblastic Leukemia/Lymphoma (Precursor B Cell Acute Lymphoblastic Leukemia, B-ALL)
***** Major Translocation Fusion Gene Abnormalities in B Cell ALL
****** t(9;22)(q34;q11.2)/1BCR-ABL1 is found in approximately 3% to 4% of childhood B-lineage ALL, but it occurs in 20% to 25% of adult B-ALL
***** Prenatal Origins of Childhood Leukemias
***** BCR-ABL1–Like B-Acute Lymphoblastic Leukemia
***** T Cell Lymphoblastic Leukemia/Lymphoma
**** Molecular diagnosis of myeloproliferative neoplasms
***** Chronic Myelogenous Leukemia with t(9;22) (q34;q11)/BCR-ABL1 Positive
***** Ph-Negative Myeloproliferative Neoplasms: Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis—JAK2, MPL Gene, and CALR Mutations
***** Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia with CSF3R Gene Mutation
***** Mastocytosis and the KIT D816V Gene Mutation
*** Neoplastic disorders associated with eosinophilia
*** Molecular diagnosis of non-hodgkin lymphomas
**** Rationale for molecular genetic analysis in the lymphoid disorders
**** Antigen receptor gene rearrangements for clonality determination
***** Mechanism of Antigen Receptor Gene Rearrangements
***** Techniques to Detect Antigen Receptor Gene Rearrangements: Southern Blot Hybridization
****** Advantages and Shortcomings of Southern Blot Hybridization and Polymerase Chain Reaction for Lymphoid Clonality Assessment
**** Molecular detection and significance of common lymphoma-associated chromosomal translocations
***** t(14;18)/BCL2-IGH Abnormality in Follicular and Diffuse Large B Cell Lymphomas
***** t(11;14)/CCND1-IGH Abnormality in Mantle Cell Lymphoma
***** MALT1, BCL10, and FOXP1 Gene Abnormalities in Extranodal Marginal Zone B Cell Lymphomas
***** Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Molecular and Cytogenetic Prognostic Markers
***** Diffuse Large B Cell Lymphomas: Role of BCL6 and MYC Gene Abnormalities and Classification Based on Gene Expression Profiling
***** MYC Gene Translocations in Burkitt Lymphomas and “High-Grade” B Cell Lymphomas, Unclassifiable
***** MYD88 Mutation in Non-Hodgkin B Cell Lymphoma
***** ALK Gene Abnormalities in Anaplastic Large Cell Lymphomas
***** TCL1A Gene Abnormalities in T Cell
Prolymphocytic Leukemia
***** The Implication of Next Gene Sequencing (NGS) in Hematolymphoid Lesions
*** Emerging technologies impacting molecular diagnosis and prognosis prediction in hematolymphoid neoplasia
** 77. Molecular genetic pathology of solid tumors
** 78. High-throughput genomic and proteomic technologies in the postgenomic era
